CA2455567A1 - Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same - Google Patents

Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same Download PDF

Info

Publication number
CA2455567A1
CA2455567A1 CA002455567A CA2455567A CA2455567A1 CA 2455567 A1 CA2455567 A1 CA 2455567A1 CA 002455567 A CA002455567 A CA 002455567A CA 2455567 A CA2455567 A CA 2455567A CA 2455567 A1 CA2455567 A1 CA 2455567A1
Authority
CA
Canada
Prior art keywords
beta
lapachone
pharmaceutically acceptable
carrier molecule
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002455567A
Other languages
English (en)
French (fr)
Inventor
Zhiwei Jiang
Dasharatha G. Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2455567A1 publication Critical patent/CA2455567A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CA002455567A 2001-07-31 2002-07-31 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same Abandoned CA2455567A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30893501P 2001-07-31 2001-07-31
US60/308,935 2001-07-31
US09/975,776 2001-10-10
US09/975,776 US6962944B2 (en) 2001-07-31 2001-10-10 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
PCT/US2002/024262 WO2003011224A2 (en) 2001-07-31 2002-07-31 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same

Publications (1)

Publication Number Publication Date
CA2455567A1 true CA2455567A1 (en) 2003-02-13

Family

ID=26976533

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002455567A Abandoned CA2455567A1 (en) 2001-07-31 2002-07-31 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same

Country Status (13)

Country Link
US (1) US6962944B2 (enExample)
EP (1) EP1420777A4 (enExample)
JP (1) JP2005507861A (enExample)
KR (1) KR100734341B1 (enExample)
CN (1) CN1561209A (enExample)
AU (1) AU2002313713B2 (enExample)
BR (1) BR0211613A (enExample)
CA (1) CA2455567A1 (enExample)
EA (1) EA007075B1 (enExample)
IL (2) IL160108A0 (enExample)
MX (1) MXPA04000994A (enExample)
NZ (1) NZ531335A (enExample)
WO (1) WO2003011224A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
EP1435908A4 (en) * 2001-09-13 2006-03-15 Korea Inst Sci & Tech Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
US6890950B2 (en) * 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
CA2492772A1 (en) * 2002-07-17 2004-01-22 Chiang J. Li Activated checkpoint therapy and methods of use thereof
AU2003293333A1 (en) * 2002-12-02 2004-06-23 Arqule, Inc. Method of treating cancers
JP2007512378A (ja) * 2003-11-26 2007-05-17 アークル インコーポレイテッド 放射線障害から保護するためのβ−ラパコンの使用
EP1722777A2 (en) * 2004-02-20 2006-11-22 Arqule, Inc. Use of beta-lapachone for the treatment of pancreatic cancer
CA2555941A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treatment of colon cancer
EP1729760A2 (en) * 2004-02-20 2006-12-13 Arqule, Inc. Use of beta-lapachone for the treatment of lung cancer
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
CA2583700A1 (en) * 2004-08-11 2006-02-23 Arqule, Inc. Quinone prodrug compositions and methods of use
US8614228B2 (en) * 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
ITMI20041763A1 (it) * 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
TW200824692A (en) * 2006-08-21 2008-06-16 Arqule Inc Novel lapachone compounds and methods of use thereof
US7790765B2 (en) * 2007-04-30 2010-09-07 Arqule, Inc. Hydroxy sulfonate of quinone compounds and their uses
CN101801937A (zh) 2007-06-22 2010-08-11 艾科尔公司 喹唑啉酮化合物及其使用方法
EP2193140B1 (en) 2007-08-27 2016-11-02 1Globe Health Institute LLC Compositions of asymmetric interfering rna and uses thereof
JP4792128B2 (ja) 2007-10-12 2011-10-12 アークル インコーポレイテッド 癌に対するｈｓｐ９０阻害剤としての５−（２−ヒドロキシフェニル）テトラゾール
US8067459B2 (en) * 2007-10-16 2011-11-29 Arqule, Inc. Lapachone compounds and methods of use thereof
KR101405823B1 (ko) 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
KR20090073381A (ko) * 2007-12-31 2009-07-03 주식회사 머젠스 심장질환의 치료 및 예방을 위한 약제 조성물
KR101528265B1 (ko) * 2010-04-16 2015-06-11 코웨이 주식회사 베타-라파콘을 유효성분으로 포함하는 주름개선용 화장료 조성물
CN103429235A (zh) * 2010-12-15 2013-12-04 赖鸿政 用于治疗癌症的化合物及其应用
KR101583755B1 (ko) 2012-10-29 2016-01-19 코웨이 주식회사 베타-라파콘을 유효성분으로 포함하는 신경계 질환 예방 및 치료용 조성물
RU2530886C1 (ru) * 2013-06-24 2014-10-20 Государственное бюджетное учреждение "Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан" Водорастворимый комплекс включения бета-циклодекстрин-гистохром, обладающий пролонгированным антиоксидантным действием
JP7042529B2 (ja) * 2018-01-18 2022-03-28 ナディアンバイオ・リミテッド 脱毛の予防または軽減のための、有効成分としてダンニオンを含む組成物
CN112076157B (zh) * 2019-06-14 2022-04-26 首都医科大学 拉帕醇纳米脂质体制剂及其制备方法和应用
TWI832069B (zh) * 2020-07-10 2024-02-11 南韓商娜迪安生物公司 用於預防或治療癌症且含有萘醌系化合物及免疫檢查點抑制劑作為活性成分的藥學組成物
KR20240014533A (ko) 2021-05-29 2024-02-01 1글로브 헬스 인스티튜트 엘엘씨 신규한 유전자 침묵 기술로서의 짧은 듀플렉스 dna 및 이의 용도
CA3221935A1 (en) 2021-05-29 2022-12-08 1Globe Health Institute Llc Asymmetric short duplex dna as a novel gene silencing technology and use thereof
KR20240096905A (ko) * 2021-12-15 2024-06-26 신라젠(주) 변형된 베타-사이클로덱스트린을 포함하는 약제학적 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827452A (en) 1955-05-31 1958-03-18 Univ Minnesota Stabilization of materials
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
HU184066B (en) 1979-12-28 1984-06-28 Chinoin Gyogyszer Es Vegyeszet Plant growth regulating substance and process for preparing such compound
HU181703B (en) 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
US4371673A (en) 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
AU558787B2 (en) 1981-01-23 1987-02-12 Wellcome Foundation Limited, The Inclusion complexes of cyclodextrins and cardiac clycosides
JPS57126802A (en) 1981-01-30 1982-08-06 Mitsubishi Petrochem Co Ltd Benzophenone-3,3'-disulfonate-capped compound of beta-cyclodextrin
JPS57200361A (en) 1981-06-03 1982-12-08 Sumitomo Chem Co Ltd "indomethacin(r)" pharmaceutical with low irritant action
US4383992A (en) 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58144376A (ja) 1982-02-23 1983-08-27 Sumitomo Chem Co Ltd ベンゾジアゼピン誘導体−シクロデキストリン包接化合物
HU190818B (en) 1982-11-09 1986-11-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing complexes of piperonyl-butoxide-cyclodextrin
HU190584B (en) 1983-03-11 1986-09-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara,Rt,Hu Process for the production of heptakis/2,6-di-o-methyl-beta-cyclodextrin
DE3400488A1 (de) 1983-03-16 1984-09-20 Kraftwerk Union AG, 4330 Mülheim Elektrohydraulischer kompaktantrieb fuer ventile von turbomaschinen, insbesondere turbinen
EP0146841A3 (de) 1983-12-17 1986-11-20 Consortium für elektrochemische Industrie GmbH Wasserlösliche Mischether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
EP0147685B1 (de) 1983-12-17 1989-04-26 Hoechst Aktiengesellschaft Ether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
MC1710A1 (fr) * 1984-11-26 1986-09-22 Ciba Geigy Ag Composes azotes de derives oxo
MC1711A1 (fr) 1984-11-26 1986-09-22 Ciba Geigy Ag Compose alkylidene-dioxy
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
WO1994004145A1 (en) 1992-08-21 1994-03-03 Dana Farber Cancer Institute Treatment of human viral infections
WO1996011005A2 (en) 1994-10-06 1996-04-18 Atlas Leon T Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
US5763625A (en) 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
WO1997007797A1 (en) * 1995-08-25 1997-03-06 Dana-Farber Cancer Institute Treatment of human prostate disease with beta-lapachone derivatives
US6245807B1 (en) 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
AU6901296A (en) * 1995-08-24 1997-03-19 Dana-Farber Cancer Institute Beta-lapachone derivatives as antitumor agents
US5883270A (en) 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
US5824700A (en) 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
US6664288B1 (en) 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
ATE407676T1 (de) 2000-02-28 2008-09-15 Univ British Columbia Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
US6890950B2 (en) 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto

Also Published As

Publication number Publication date
CN1561209A (zh) 2005-01-05
JP2005507861A (ja) 2005-03-24
EP1420777A2 (en) 2004-05-26
KR20040054667A (ko) 2004-06-25
EA200400242A1 (ru) 2004-12-30
AU2002313713B2 (en) 2007-03-29
EA007075B1 (ru) 2006-06-30
KR100734341B1 (ko) 2007-07-03
WO2003011224A3 (en) 2003-05-08
MXPA04000994A (es) 2005-02-17
NZ531335A (en) 2007-08-31
WO2003011224A2 (en) 2003-02-13
US20030091639A1 (en) 2003-05-15
EP1420777A4 (en) 2009-03-04
BR0211613A (pt) 2004-11-09
IL160108A0 (en) 2004-06-20
IL192937A0 (en) 2009-02-11
US6962944B2 (en) 2005-11-08

Similar Documents

Publication Publication Date Title
AU2002313713B2 (en) Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
AU2002313713A1 (en) Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US7074824B2 (en) Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US11491226B2 (en) Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound
AU2016202145B2 (en) Methods of Increasing Solubility of Poorly Soluble Compounds and Methods of Making and Using Formulations of Such Compounds
JP4334229B2 (ja) プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
EP2480207B1 (en) Micelle encapsulation of therapeutic agents
Tommasini et al. Combined effect of pH and polysorbates with cyclodextrins on solubilization of naringenin
JP5021305B2 (ja) 水溶性ジテルペンの調製方法およびその適用
EP0717638A1 (en) Improved pharmaceutical formulation
EP1773294A2 (en) Compositions for delivering highly water soluble drugs
WO2024216339A1 (en) Topical protein based formulation
Şen et al. THE EFFECT OF CYCLODEXTRINS ON THE IN VITRO CHARACTERISTICS OF SEMISOLID FORMULATIONS OF all-trans RETINOIC ACID.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued